Indications
Therapeutic Asset Ratings
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Diphenhydramine
Neoplasm
Hellenic Society of Hematology
P2
BBB
(72)
Everolimus
Neoplasm
Uppsala University Hospital
P2
BBB
(72)
Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer
Cancer
Eli Lilly and Company
P2
BBB
(72)
Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer
Renal Cell Carcinoma
Novartis Pharmaceuticals
P2
BBB
(72)
Irinotecan
Pancreatic Acinar Cell Carcinoma
Artios Pharma Ltd
P2
BBB
(72)
Melphalan
Acute Leukemia
Center for International Blood and Marrow Transplant Research
P2
BBB
(72)
Melphalan
Plasma Cell Leukemia
National Cancer Institute (NCI)
P2
BBB
(72)
Melphalan
B-Cell Chronic Lymphocytic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
P2
BBB
(72)
Mesna
Acute Myeloid Leukemia
Center for International Blood and Marrow Transplant Research
P2
BBB
(72)
Mesna
Myelodysplastic Syndrome
Center for International Blood and Marrow Transplant Research
P2
BBB
(72)
Nivolumab
Castration-Resistant Prostate Carcinoma
Rana McKay, MD
P2
BBB
(72)
Nivolumab
Colorectal Adenocarcinoma
University Hospital, Akershus
P2
BBB
(72)
Nivolumab
Colorectal Carcinoma
Fred Hutchinson Cancer Center
P2
BBB
(72)
Nivolumab
Lymphoma
National Cancer Institute (NCI)
P2
BBB
(72)
Nivolumab
Peripheral T-Cell Lymphoma, Not Otherwise Specified
University of Michigan Rogel Cancer Center
P2
BBB
(72)
Oxaliplatin
B-Cell Non-Hodgkin Lymphoma
Mwanasha Merrill, MD
P2
BBB
(72)
Pembrolizumab
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Roswell Park Cancer Institute
P2
BBB
(72)
Pembrolizumab
Estrogen-Receptor Negative Breast Cancer
Massachusetts General Hospital
P2
BBB
(72)
Pembrolizumab
Marginal Zone Lymphoma
University of Ulm
P2
BBB
(72)
Pembrolizumab
Mycosis Fungoides
Sorrento Therapeutics, Inc.
P2
BBB
(72)
Pembrolizumab
Pancreatic Adenocarcinoma
Mayo Clinic
P2
BBB
(72)
Pembrolizumab
Progesterone-Receptor Negative Breast Cancer
Massachusetts General Hospital
P2
BBB
(72)
Pembrolizumab
Metastatic Prostate Carcinoma
CuraCell TX AB
P2
BBB
(72)
Pembrolizumab
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Mayo Clinic
P2
BBB
(72)
Pembrolizumab
Sarcoma
Essen Biotech
P2
BBB
(72)
Showing 2776 to 2800 of 42,289 assets
Previous
Page 112 of 1692
Next